Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02590393 · ClinicalTrials.gov registry record · Phase 1
The Role of Nicotine and Non-Nicotine Alkaloids in E-Cigarette Use and Dependence
A Phase 1 study of Nicotine Dependence, sponsored by Duke University.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT02590393 is a Phase 1 study of Nicotine Dependence that has completed, run by Duke University. The registered enrollment target is 20 participants, below the 186-participant average among 67 other Nicotine Dependence trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02590393, a Phase 1 study of Nicotine Dependence, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The advent of electronic cigarette (e-cigarette) technologies represents one of the most significant developments in the last several decades, and provides a novel and promising strategy for substantially reducing the morbidity and mortality associated with smoking. However, serious concerns have been raised regarding the possibility that e-cigarettes will sustain a dependency on nicotine and that they may lead to continued use of conventional cigarettes known to be extremely harmful to health. Cigarette addiction critically involves a dependence on nicotine, but it is likely that other tobacco constituents contribute to dependence as well. Recent evidence suggests that non-nicotine tobacco alkaloids, or NNTAs (including anabasine, anatabine, nornicotine, and myosmine) may play a role in tobacco dependence. These alkaloids have been shown to augment the reinforcing effects of nicotine in animal models and to affect cravings in human smokers. E-cigarettes contain variable quantities of nicotine and NNTAs, but there is virtually no information available concerning the role of e-cigarette nicotine or NNTA content in influencing the concurrent use of cigarettes and e-cigarettes, when smokers attempt to switch from conventional combustible cigarettes to e-cigarettes. Additionally, it is not known whether the presence of nicotine and NNTAs in e- cigarettes may sustain dependence, making it difficult to relinquish these products. The proposed project will assess the acceptability, extent of switching behavior, and degree of dependence maintained when smokers are provided with e-cigarettes containing nicotine and NNTAs.
Conditions Studied
Interventions
- COMBINATION_PRODUCT E-cigarettes
Study Locations (1)
North Carolina
- Duke Center for Smoking Cessation - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2021-05-21 |
| Est. Completion | 2022-01-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02590393
The ClinicalTrials.gov registry entry for NCT02590393 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 186-participant average among 67 other Nicotine Dependence trials with a reported enrollment target (89% lower). The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Nicotine Dependence appearing as the primary indexed condition, and to 1 intervention - of which E-cigarettes is the first listed.
NCT02590393 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT02590393 about?
NCT02590393 is a clinical study titled "The Role of Nicotine and Non-Nicotine Alkaloids in E-Cigarette Use and Dependence". The advent of electronic cigarette (e-cigarette) technologies represents one of the most significant developments in the last several decades, and provides a novel and promising strategy for substantially reducing the morbidity and mortality associated with smoking. However, serious concerns have be...
What is the current status of trial NCT02590393?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2021-05-21. Estimated completion is 2022-01-13.
What conditions does trial NCT02590393 study?
This clinical trial studies the following conditions: Nicotine Dependence.
What interventions are being tested in trial NCT02590393?
The interventions under investigation include: E-cigarettes (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT02590393?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02590393 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Nicotine Dependence
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Effects of Cannabidiol on Stress and Nicotine Withdrawal
RECRUITING · Phase 1
-
Overcoming Nicotine Dependence to Enable Quitting
RECRUITING · Phase 1
-
Comparative Pharmacokinetics and Pharmacodynamics of Synthetic Nicotine
RECRUITING · Phase 1
-
Brain Reaction to Treatment of Nicotine Dependence
COMPLETED · Phase 1
-
Effects of Nicotine on Elements of Attentions in Smokers and Nonsmokers
COMPLETED · Phase 1
-
New Approaches to Smoking Cessation in Heavy Drinkers
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.